Khaitan & Co advised Samvardhana Motherson International Ltd in connection with its issuance of listed non-convertible debentures, aggregating up to INR 2025 crores, bearing a coupon of 6.80% p.a. payable annually with a tenure of 5 years, on a private placement basis (“Issue”). The Issue has been assigned “AAA / Stable” ratings by various credit rating agencies. SBI Capital Markets Limited played a pivotal role as sole arranger and anchor investor to the Issue.

Khaitan & Co acted as legal counsel to Kalpataru Ltd in relation to the initial public offering of equity shares aggregating to INR 15,900.00 million. The book running lead managers to the issue were ICICI Securities Ltd, JM Financial Ltd and Nomura Financial Advisory and Securities (India) Pvt Ltd.

Khaitan & Co advised Torrent Pharmaceuticals Ltd on its proposed acquisition of a stake in J.B. Pharma from KKR, valuing J.B. Pharma at INR 25,689 crores. The deal includes acquisition of KKR’s 46.39% stake in J.B. Pharma for INR 11,917 crores, an open offer for acquisition of up to 26% stake of J.B. Pharma, a potential 2.80% stake purchase from certain employees and a proposed merger of J.B. Pharma with Torrent. 

Khaitan & Co advised Galderma Holdings S.A., acting in India through Galderma India Pvt Ltd (‘Galderma’) which has been facing significant challenges due to the increase in sale of counterfeit goods bearing its trademarks ‘CETAPHIL’, on the e-commerce platforms as well as in local markets. On 18 June 2025, the Bombay High Court granted Galderma a John Doe order, which allowed Galderma to conduct search and seizure operations. Following the order, Galderma’ and Khaitan & Co.

Khaitan & Co successfully advised and represented, Concentrix Daksh Services India Pvt Ltd (“Concentrix”) in a commercial suit before the Commercial Court, Gurugram District Court and secured a favourable money decree against Triller Inc. (“Triller”), a US-based technology company, in less than 2 years. The dispute arose from a Customer Agreement and Scope of Work under which Concentrix had been providing content moderation services to Triller and failure of Triller to pay outstanding service charges.

Khaitan & Co advised Premji Invest on their participation in the Series C funding round of Indiejewel Fashions Pvt Ltd (dba Giva). The Series C funding round was led by Creaegis and participated by Premji Invest, Epiq Capital, and Edelweiss Discovery Fund.

Khaitan & Co acted as legal advisors to Softbank Vision Fund in relation to redomiciling of Meesho Inc. from US (i.e., Delaware incorporated entity) to India by way of merger of Meesho Inc. into and with Meesho under the NCLT route. 

Khaitan & Co advised a hotel owner in relation to a hotel management agreement with Dusit Hotels for a proposed 120 key hotel in Lonavala.

Khaitan & Co acted as the legal counsel to Credit Agricole Corporate and Investment Bank in relation to a term loan facility aggregating up to INR 250 crores extended to Greenko RJ01 IREP Pvt Ltd for funding project costs.

The Firm acted as the lender’s legal counsel and had the primary role of: (i) drafting, negotiating and finalizing the financing documents; (ii) assisting in completion of the conditions precedent/ conditions subsequent; and (iii) execution assistance and closing of the transaction.

Khaitan & Co advised Aranda Investments Pte. Ltd. and Macritchie Investments Pte. Ltd. (Temasek entities) on corporate and IPO related aspects in connection with the filing the draft red herring prospectus by Pine Labs Limited for the proposed IPO comprising of a fresh issue aggregating INR 26,000.00 million and an offer for sale of equity shares.

The IPO filing was achieved after successful reverse flip of Pine Labs to India.